Related Information

• FDA Drug Safety Communication: Serious allergic reactions reported with the use of Saphris (asenapine maleate)
  9/1/2011
• FDA Drug Safety Communication: Medication errors resulting from confusion between risperidone (Risperdal) and ropinirole (Requip)
  6/13/2011
• FDA Drug Safety Communication: Antipsychotic drug labels updated on use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns
  2/22/2011
• Podcast for Healthcare Professionals: Antipsychotic drug labels updated on use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns
  2/23/2011
• Information for Healthcare Professionals: Olanzapine/fluoxetine (marketed as Symbyax)
  7/2006
• Historical Information on Atypical Antipsychotic Drugs
• Information on Conventional Antipsychotics

Labeling and Regulatory History from Drugs@FDA

• Aripiprazole (marketed as Abilify) Approval History and Labeling Information
• Asenapine Maleate (marketed as Saphris) Prescribing and Label Information
• Clozapine (marketed as Clozaril) Approval History and Labeling Information
• Iloperidone (marketed as Fanapt) Approval History and Labeling Information
• Lurasidone (marketed as Latuda) Approval History and Labeling information
• Olanzapine (marketed as Zyprexa) Approval History and Labeling Information
• Olanzapine/Fluoxetine (marketed as Symbyax) Prescribing and Label Information
• Paliperidone (marketed as Invega) Approval History and Labeling Information
• Quetiapine (marketed as Seroquel) Prescribing and Label Informaiton
• Risperidone (marketed as Risperdal) Prescribing and Label Information
• Ziprasidone (marketed as Geodon) Prescribing and Label Information

Contact FDA